Caribou Biosciences, Inc. experienced a 45% share price decline after presenting puzzling results for their product candidate CB-010 in a Phase 1 clinical trial. CB-010 showed limited efficacy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback